Table 5 Most common adverse events (any grade)
Any Grade, n (%) | Apatinib Based N = 56 | Chemotherapy Based N = 107 | P |  | Apatinib plus Chemotherapy N = 34 | Chemotherapy Alone N = 97 | P |
|---|---|---|---|---|---|---|---|
Hematological events | Â | Â | Â | Â | Â | Â | Â |
Neutropenia | 45 (80.4) | 88 (82.2) | 0.77 | Â | 26 (76.5) | 79 (81.4) | 0.53 |
Anemia | 18 (32.1) | 57 (53.3) | 0.01 | Â | 8 (23.5) | 53 (54.6) | 0.002 |
Thrombocytopenia | 10 (17.9) | 17 (15.9) | 0.75 | Â | 7 (20.6) | 17 (17.5) | 0.69 |
Non-hematological events | Â | Â | Â | Â | Â | Â | Â |
Peripheral neuropathy | 15 (26.8) | 51 (47.7) | 0.01 | Â | 8 (23.5) | 45 (46.4) | 0.02 |
Nausea/vomiting | 8 (14.3) | 39 (36.4) | 0.003 | Â | 4 (11.8) | 38 (39.2) | 0.006 |
Diarrhea | 2 (3.6) | 16 (15.0) | 0.05 | Â | 0 | 16 (16.5) | 0.01 |
AST/ALT alterations | 19 (33.9) | 36 (33.6) | 0.97 | Â | 9 (26.5) | 32 (33.0) | 0.48 |
Fatigue | 27 (48.2) | 46 (43.0) | 0.52 | Â | 12 (35.3) | 39 (40.2) | 0.61 |
Proteinuria | 13 (23.2) | 3 (2.8) | < 0.001 |  | 9 (26.5) | 3 (3.1) | < 0.001 |
Hypertension | 33 (58.9) | 2 (1.9) | < 0.001 |  | 21 (61.8) | 1 (1.0) | < 0.001 |
Hand-foot Syndrome | 22 (39.3) | 8 (7.5) | < 0.001 |  | 12 (35.3) | 8 (8.2) | < 0.001 |
Alopecia | 29 (51.8) | 78 (72.9) | 0.007 | Â | 17 (50.0) | 72 (74.2) | 0.009 |